We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bitop AG Announces Start of Clinical Trial with Ectoin Inhalation Solution

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bitop AG Announces Start of Clinical Trial with Ectoin Inhalation Solution"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

The present clinical study is a single-center efficacy and feasibility study involving patients with inflammation and airway obstruction in Germany. After the successful feasibility a long term study extension will investigate the effect of Ectoin Inhalation Solution of lung function decline, lung ageing and inflammation. bitop makes use of Pari Pharma’s eFlow nebulisation technology to obtain optimal delivery of the Ectoin Inhalation Solution into the lungs.

“Environmental pollution of the lungs poses a growing problem for the inhabitants of industrialized countries, leading to diseases like COPD with a high economic burden. The local application of cell-protection molecules like Ectoin opens up new options for treatment in this field” states Prof. Ursula Kraemer at the Leibniz-Institut für Umweltmedizinische Forschung.

Recent clinical studies with Ectoin-containing medical devices show excellent results in efficacy and safety in the treatment of allergic rhinitis and conjunctivitis or atopic dermatitis.

Ectoin Inhalation Solution has already shown marked therapeutic efficacy in the treatment of mild asthma in humans and in animal models of nanoparticle-induced inflammatory reaction in the lungs, allergen induced asthma.

"Ectoin-containing medical devices have already shown very positive effects in different diseases. We hope that we can show in this study that Ectoin Inhalation Solution can be used to protect individuals against unavoidable environmental nanoparticle-induced inflammatory reaction in the lung” says Dr. Andreas Bilstein, Head of Medical Device Development at bitop AG.